Navigation Links
Intarcia Therapeutics Announces Presentation of Final Results From,a Phase 2 Combination Study for the Treatment of Hepatitis C at the,Digestive Disease Week Conference

Potent synergy, activity and patient tolerance observed in Genotype 1 patients support development of Omega DUROS(R) continuous delivery therapy

WASHINGTON, May 21, 2007 /PRNewswire/ -- Intarcia Therapeutics, Inc., a privately held biopharmaceutical company, today announced the presentation of final results from a Phase 2 study comparing the combination of injectable omega interferon and ribavirin to omega interferon alone in treatment-naive patients with genotype 1 chronic hepatitis C. The results demonstrate that omega interferon in combination with ribavirin is well tolerated and shows robust antiviral activity that is comparable to published data on the use of alpha interferon plus ribavirin in similar patient populations. The 72-week sustained viral response (SVR) data are being presented today at the Digestive Disease Week Conference in Washington, DC by Bruce R. Bacon, MD, Professor of Internal Medicine, Saint Louis University Medical Center, St. Louis, Missouri.

This Phase 2 study of daily subcutaneous omega interferon injections provides Intarcia with safety and clinical response data to support development of omega interferon delivered by continuous release from the DUROS(R) device.

"The safety and SVR rates achieved in this phase 2 study are encouraging in that they indicate that the combination of omega interferon and ribavirin may produce response rates which are similar to those achieved with alpha interferon and ribavirin in patients with HCV genotype-1," said Dr. Bacon. "The positive results of this study allow us to proceed with the evaluation of continuous delivery of omega interferon delivered with the DUROS device. A trial evaluating dose response of the Omega DUROS device is expected to begin in the near future."

The Phase 2 trial compared the safety and antiviral response of omega interferon alone with omega interferon in combination with ribavirin in 102 interferon-na
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Intarcia Therapeutics Announces Final Results From a Phase 2 Study of Injectable Omega Interferon plus Ribavirin for the Treatment of Hepatitis C Genotype-1
2. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
3. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
4. CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa
5. Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics
6. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
7. Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical Study
8. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
9. Orexigen Therapeutics to Present Data on Contrave Impact on Visceral Fat and Insulin Resistance at American Diabetes Association 67th Scientific Sessions in Chicago June 23
10. Allos Therapeutics Reports Results for Phase 3 Enrich Study of Efaproxyn in Women With Brain Metastases Originating From Breast Cancer
11. Trophos Publishes ALS Article in Journal of Pharmacology and Experimental Therapeutics
Post Your Comments:
(Date:3/30/2015)...  Cochlear Corporation Vice President of U.S. Sales ... join Valencia Technologies ( www.valenciatechnologies.com ) and his ... who is the CEO of Valencia.  Schloffman will ... be responsible for generating enthusiasm and support for ... coin-sized neuromodulation device in the treatment of resistant ...
(Date:3/30/2015)... --  MultiVir Inc. ("MultiVir"), a clinical-stage gene therapy ... the treatment of multiple oncological indications, today announced that ... S-1 with the U.S. Securities and Exchange Commission ("SEC") ... of its common stock. The number of shares to ... offering have not yet been determined. MultiVir has applied ...
(Date:3/30/2015)... 2015   GlassesUSA , the online retailer specializing ... in new financing led by Viola Private Equity , ... GlassesUSA,s aggressive business growth and accelerate their expansion as a ... both B2C and B2B. GlassesUSA was founded in ... Rothman , and CTO Roy Yamner . Leveraging their ...
Breaking Medicine Technology:Cochlear VP of U.S. Sales Jerry Schloffman Accepts Chief of Market Development Position at Valencia Technologies 2MultiVir Files Registration Statement for Proposed Initial Public Offering 2GlassesUSA.com Raises $12.5 Million Growth Round Led By Viola Private Equity 2GlassesUSA.com Raises $12.5 Million Growth Round Led By Viola Private Equity 3
... Mass., June 04, 2007 /PRNewswire-FirstCall/ -- Boston,Scientific ... article,in the Journal of of Cardiology (JACC) ... the Company's second-generation,TAXUS(R) Liberte(TM)(1) paclitaxel-eluting stent system. ... JACC concluded that the shorter,procedure time and ...
... Clinical Data on Thalidomide in Multiple Myeloma,Presented at ... CHICAGO, June 04, 2007 /PRNewswire-FirstCall/ -- Pharmion,Corporation today ... study,demonstrating that the addition of Thalidomide to standard ... patients aged 75,or older with newly diagnosed multiple ...
Cached Medicine Technology:Positive Results for Second-Generation Taxus Liberte Coronary Stent,System Highlighted in Journal of American College of Cardiology 2Positive Results for Second-Generation Taxus Liberte Coronary Stent,System Highlighted in Journal of American College of Cardiology 3Positive Results for Second-Generation Taxus Liberte Coronary Stent,System Highlighted in Journal of American College of Cardiology 4Adding Thalidomide to Standard Therapy Improves Survival in Newly,Diagnosed Multiple Myeloma Patients Over Age 75 2Adding Thalidomide to Standard Therapy Improves Survival in Newly,Diagnosed Multiple Myeloma Patients Over Age 75 3Adding Thalidomide to Standard Therapy Improves Survival in Newly,Diagnosed Multiple Myeloma Patients Over Age 75 4Adding Thalidomide to Standard Therapy Improves Survival in Newly,Diagnosed Multiple Myeloma Patients Over Age 75 5Adding Thalidomide to Standard Therapy Improves Survival in Newly,Diagnosed Multiple Myeloma Patients Over Age 75 6
(Date:3/30/2015)... 31, 2015 Wireless Analytics, LLC ... has been announced as one of the Boston Business ... fastest-growing private companies in Massachusetts. The list represents ... revenue growth from 2011 through 2014. 2015 marks ... Journal has recognized Wireless Analytics’s revenue growth. The ...
(Date:3/30/2015)... NY (PRWEB) March 31, 2015 ... Owner / Operator for Diamond Pharmacy Services, as ... Mitchell is recognized with this prestigious distinction for ... organization of professional women in the country, spanning ... of Professional Women is a powerfully vibrant networking ...
(Date:3/30/2015)... Dallas-Fort Worth, TX (PRWEB) March 31, 2015 ... has served as an advocate for the provision ... nationally-recognized standards and through its survey and accreditation ... process, education, and research, AAAHC aims to promote ... care organizations must undergo rigorous self-assessments and on-site ...
(Date:3/30/2015)... 2015 Hosted by the California ... free, two-day dental clinic in Sacramento provided $2 million ... , In addition to providing free dental services ... to care, CDA Cares educates the public and policymakers ... need for an adequately funded dental safety net, which ...
(Date:3/30/2015)... CA (PRWEB) March 30, 2015 KIND LED’s ... LED grow light products in 2015. The excellent value and ... them to take the pole position in the race for ... feature of the KIND LED suite of grow lights is ... most plant-friendly Photosynthetic Active Radiation (PAR) wavelengths that plants are ...
Breaking Medicine News(10 mins):Health News:Wireless Analytics Growth Streak Continues; Named to Boston Business Journal’s Pacesetters Second Year In a Row 2Health News:Wireless Analytics Growth Streak Continues; Named to Boston Business Journal’s Pacesetters Second Year In a Row 3Health News:National Association of Professional Women Announces Tamara Mitchell, Owner / Operator of Diamond Pharmacy Services, a 2015 Professional Woman of the Year 2Health News:Precinct Ambulatory Surgery Center Achieves Accreditation Association for Ambulatory Health Care Accreditation 2Health News:CDA Cares Sacramento Dental Clinic Provides $2 Million in Care 2Health News:Best LED Grow Lights of 2015 Are Being Led By KIND LED 2
... to repair nerve fiber damage , , TUESDAY, April 28 ... and stabilize damage done to the myelin sheath in people ... Idec and Elan Corp shows. , MS is nervous system ... by MS patients are caused by damage to the myelin ...
... 29 /PRNewswire-Asia-FirstCall/ -- Shengtai,Pharmaceutical, Inc. (OTC Bulletin ... manufacturer and distributor of high-quality, pharmaceutical grade,glucose ... hosted a conference at the,Company,s headquarters to ... as well as conducted,high-level discussions with key ...
... 29 , - Bausch ... Campaign , Bausch & Lomb ... in its continued effort to improve the habits of,contact ... the THINK,EYEGIENE(TM) campaign, Bausch & Lomb is introducing ReNu ...
... 2009 First Quarter Reported Diluted Earnings per Share were $0.89, ... per Share, , Excluding Certain Significant Items, Increased ... First Quarter and , Increased 2%, Excluding the ... the Impact of Foreign , Exchange, was Driven ...
... 2009 AT 13.00 CET -- Advances in ... diseases and make ever more accurate diagnoses. But ... (IAEA) say that overuse of high-tech scanning procedures may ... IAEA, in collaboration with other international organizations, is developing ...
... Bill to Advance Education and Informed Consent Recommendations Established ... Cord Blood Registry (CBR), the global ... cells from umbilical cord blood, announced its support of ... entitled the "Cord Blood Education and Awareness Act of ...
Cached Medicine News:Health News:Shengtai Pharmaceutical Hosts Key Customers at Its Headquarters for Facility Tour and Technology Exchange Conference 2Health News:Shengtai Pharmaceutical Hosts Key Customers at Its Headquarters for Facility Tour and Technology Exchange Conference 3Health News:A Clear Solution for Healthy Eyes 2Health News:A Clear Solution for Healthy Eyes 3Health News:A Clear Solution for Healthy Eyes 4Health News:Wyeth Reports Earnings Results for the 2009 First Quarter 2Health News:Wyeth Reports Earnings Results for the 2009 First Quarter 3Health News:Wyeth Reports Earnings Results for the 2009 First Quarter 4Health News:Wyeth Reports Earnings Results for the 2009 First Quarter 5Health News:Wyeth Reports Earnings Results for the 2009 First Quarter 6Health News:Wyeth Reports Earnings Results for the 2009 First Quarter 7Health News:Wyeth Reports Earnings Results for the 2009 First Quarter 8Health News:Wyeth Reports Earnings Results for the 2009 First Quarter 9Health News:Wyeth Reports Earnings Results for the 2009 First Quarter 10Health News:Wyeth Reports Earnings Results for the 2009 First Quarter 11Health News:Wyeth Reports Earnings Results for the 2009 First Quarter 12Health News:IAEA calls for enhanced radiation protection of patients 2Health News:IAEA calls for enhanced radiation protection of patients 3Health News:IAEA calls for enhanced radiation protection of patients 4Health News:IAEA calls for enhanced radiation protection of patients 5Health News:Cord Blood Registry Supports Introduction of the Cord Blood Education and Awareness Act of 2009 2Health News:Cord Blood Registry Supports Introduction of the Cord Blood Education and Awareness Act of 2009 3
... ergonomic chairs with concave seats and ... Select options like seats, backrests, armrests, ... chairs are recommended for the following ... static control, health care and office. ...
... chairs with concave seats and standard-sized ... options like seats, backrests, armrests, and ... are recommended for the following environments: ... control, health care and office. • ...
... Basic ergonomic chairs with concave ... support • Select options like seats, ... • BTC/1Q chairs are recommended for ... clean room, static control, health care ...
... Basic ergonomic chairs with concave seats ... • Select options like seats, backrests, ... BTC/1Q chairs are recommended for the ... room, static control, health care and ...
Medicine Products: